CBD Effects on TRPV1 Signaling Pathways in Cultured DRG Neurons
Authors:
Open Access
- 1 September 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 13, 2269-2278
Abstract
Introduction: Cannabidiol (CBD) is reported to produce pain relief, but the clinically relevant cellular and molecular mechanisms remain uncertain. The TRPV1 receptor integrates noxious stimuli and plays a key role in pain signaling. Hence, we conducted in vitro studies, to elucidate the efficacy and mechanisms of CBD for inhibiting neuronal hypersensitivity in cultured rat sensory neurons, following activation of TRPV1. Methods: Adult rat dorsal root ganglion (DRG) neurons were cultured and supplemented with the neurotrophic factors NGF and GDNF, in an established model of neuronal hypersensitivity. Neurons were stimulated with CBD (Adven 150, EMMAC Life Sciences) at 1, 10, 100 nMol/L and 1, 10 and 50 μMol/L, 48 h after plating. In separate experiments, DRG neurons were also stimulated with capsaicin with or without CBD (1 nMol/L to10 μMol/L), in a functional calcium imaging assay. The effects of the adenylyl cyclase activator forskolin and the calcineurin inhibitor cyclosporin were determined. We also measured forskolin-stimulated cAMP levels, without and after treatment with CBD, using a homogenous time-resolved fluorescence (HTRF) assay. The results were analysed using Mann-Whitney test. Results: DRG neurons treated with 10 and 50 μMol/L CBD showed calcium influx, but not at lower doses. Neurons treated with capsaicin demonstrated robust calcium influx, which was dose-dependently reduced in the presence of low dose CBD (IC50 = 100 nMol/L). The inhibition or desensitization by CBD was reversed in the presence of forskolin and cyclosporin. Forskolin-stimulated cAMP levels were significantly reduced in CBD treated neurons. Conclusion: CBD at low doses corresponding to plasma concentrations observed physiologically inhibits or desensitizes neuronal TRPV1 signalling by inhibiting the adenylyl cyclase – cAMP pathway, which is essential for maintaining TRPV1 phosphorylation and sensitization. CBD also facilitated calcineurin-mediated TRPV1 inhibition. These mechanisms may underlie nociceptor desensitization and the therapeutic effect of CBD in animal models and patients with acute and chronic pain.Keywords
This publication has 48 references indexed in Scilit:
- Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program resultsEpilepsia, 2018
- Randomized, dose-ranging safety trial of cannabidiol in Dravet syndromeNeurology, 2018
- Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndromeProceedings of the National Academy of Sciences, 2017
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trialThe Lancet Neurology, 2016
- Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disordersEpilepsia, 2014
- Targeting CB2 receptors and the endocannabinoid system for the treatment of painBrain Research Reviews, 2009
- Cannabinoids in the management of difficult to treat painTherapeutics and Clinical Risk Management, 2008
- A Multicenter Dose-escalation Study of the Analgesic and Adverse Effects of an Oral Cannabis Extract (Cannador) for Postoperative Pain ManagementAnesthesiology, 2006
- Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trialPain, 2004
- Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patientsMultiple Sclerosis Journal, 2004